- Jul 2018
-
europepmc.org europepmc.org
-
On 2016 Aug 26, Sharanbasappa Durg commented:
The treatment of low back pain (LBP) is challenging and guidelines recommend medications with proven benefits. Further, patients’ preference should be considered in the treatment of pain. Systematic reviews (mainly of randomized controlled trials [RCTs]), with or without meta-analysis, are generally considered to provide the key evidence in the practice of evidence-based medicine.
The systematic review and meta-analysis by Abdel Shaheed C, 2017 pooled all the available clinical evidence (of RCTs) on the use of muscle relaxants (Thiocolchicoside, Carisoprodol, Tizanidine, Eperisone, Pridinol, Flupirtine, Cyclobenzaprine) for LBP. Most of the included trials evaluated the efficacy and safety of muscle relaxants in acute LBP participants. The controls were mainly either placebo or nonsteroidal anti-inflammatory drugs (NSAIDs). The study authors could have tried some meta-analysis on important physiological outcomes. This systematic review concluded that muscle relaxants provide clinically significant pain relief for acute LBP.
Similar outcomes were observed in a systematic literature review on Eperisone for LBP by Bavage S, 2016, 2016. In this systematic review, the authors found that intervention with Eperisone may be effective in acute LBP patients with less adverse effects. Further, Eperisone also improved paraspinal blood flow in chronic LBP patients.
Both the systematic reviews, however, did not find any considerably support for the use of muscle relaxants in chronic LBP patients. Though, few RCTs evaluated the efficacy and safety of muscle relaxants in chronic LBP. Future research should emphasize more on finding the clinical evidence whether muscle relaxants have beneficial effects in patients with chronic LBP.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY. -
On 2016 Aug 26, Sharanbasappa Durg commented:
None
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
europepmc.org europepmc.org
-
On 2016 Aug 26, Sharanbasappa Durg commented:
None
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY. -
On 2016 Aug 26, Sharanbasappa Durg commented:
The treatment of low back pain (LBP) is challenging and guidelines recommend medications with proven benefits. Further, patients’ preference should be considered in the treatment of pain. Systematic reviews (mainly of randomized controlled trials [RCTs]), with or without meta-analysis, are generally considered to provide the key evidence in the practice of evidence-based medicine.
The systematic review and meta-analysis by Abdel Shaheed C, 2017 pooled all the available clinical evidence (of RCTs) on the use of muscle relaxants (Thiocolchicoside, Carisoprodol, Tizanidine, Eperisone, Pridinol, Flupirtine, Cyclobenzaprine) for LBP. Most of the included trials evaluated the efficacy and safety of muscle relaxants in acute LBP participants. The controls were mainly either placebo or nonsteroidal anti-inflammatory drugs (NSAIDs). The study authors could have tried some meta-analysis on important physiological outcomes. This systematic review concluded that muscle relaxants provide clinically significant pain relief for acute LBP.
Similar outcomes were observed in a systematic literature review on Eperisone for LBP by Bavage S, 2016, 2016. In this systematic review, the authors found that intervention with Eperisone may be effective in acute LBP patients with less adverse effects. Further, Eperisone also improved paraspinal blood flow in chronic LBP patients.
Both the systematic reviews, however, did not find any considerably support for the use of muscle relaxants in chronic LBP patients. Though, few RCTs evaluated the efficacy and safety of muscle relaxants in chronic LBP. Future research should emphasize more on finding the clinical evidence whether muscle relaxants have beneficial effects in patients with chronic LBP.
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-